First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its recent attendance at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The Conference, held October 22-26, 2025, in Boston, ...

Core Insights - MAIA Biotechnology, Inc. has published a manuscript on its Phase 2 THIO-101 clinical trial in the journal Cells, focusing on the management of non-small cell lung cancer (NSCLC) in the context of immunotherapy [1][2] - The company emphasizes the significance of its novel combination strategy using ateganosine with a checkpoint inhibitor, which shows promising results for patients with high unmet medical needs [2] Company Overview - MAIA Biotechnology is a clinical-stage biopharmaceutical company dedicated to developing targeted immunotherapies for cancer, with a focus on first-in-class drugs that aim to improve and extend the lives of cancer patients [4] - The lead program, ateganosine (THIO), is a telomere-targeting agent currently in clinical development for NSCLC patients with telomerase-positive cancer cells [4] Product Details - Ateganosine is a first-in-class investigational agent that targets telomeres, playing a crucial role in cancer cell survival and resistance to therapies [3] - The treatment has shown to induce significant tumor regression in advanced cancer models by activating both innate and adaptive immune responses [3]